Crystalline form of indazole derivative and preparation method thereof
By developing maleate IV crystal form of an indazole derivative, the problem of estrogen receptor resistance caused by mutation in ESR1 gene was solved, and effective inhibition of wild-type and mutant receptors was achieved, providing New treatment options.
Patent Information
- Application Number
- CN202410718911.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-05
- Filing Date
- 2024-06-05
- Publication Date
- 2024-12-06
AI Technical Summary
About 30% of breast cancer patients will have ESR1 gene mutations after receiving aromatase inhibitors, resulting in estrogen receptor-positive breast cancer resistance to treatment, and existing estrogen receptor antagonists will mutant receptors The inhibitory activity of the estrogen receptor is reduced and it is unable to effectively antagonize the activity of the estrogen receptor.
Develop a maleate IV crystal form of an indazole derivative, determine its crystalline form through the characteristic peak position of the X-ray powder diffraction spectrum, and the preparation method includes dissolving and crystallizing the compound and maleic acid in a specific solvent. Precipitation, filtering, washing and drying to form a pharmaceutical composition for the treatment of estrogen receptor-mediated diseases.
This compound has strong inhibitory activity on both wild-type and mutant estrogen receptors, and can exert a longer efficacy through covalent binding, providing a new therapeutic option for ESR1 gene mutations and improving drug resistance The therapeutic effect of breast cancer.
Smart Images

Figure CN119080740A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a crystalline form of an indazole derivative and a preparation method thereof, and belongs to the field of medicine. Background Art
[0002] Breast cancer is one of the most common malignant tumors in women. According to GLOBALCAN statistics in 2012 (CACANCER J CLIN 2015; 65:87–108), there are approximately 1.7 million new cancer cases and 520,000 deaths per year worldwide. Both the incidence and mortality rates of breast cancer rank first among malignant tumors in women.
[0003] About 70% of breast cancer patients are estrogen receptor (ER) positive breast cancer. In the treatment of this part of breast cancer patients, endocrine therapy plays an important role. Endocrine therapy is mainly divided into three categories, namely aromatase inhibitor (AI), which can inhibit the conversion of androgen into estrogen and reduce the level of estrogen in the body, selective estrogen receptor modulator (SERM), which antagonizes the activity of estrogen receptors, and selective estrogen receptor degrader (SERD), which can not only antagonize the activity of estrogen receptors, but also promote the degradation of receptors (Pharmacol Ther. 2017Dec 28). Although endocrine therapy is the first choice for estrogen receptor positive breast cancer, about 30% of patients who receive adjuvant therapy will relapse, and almost all patients with metastatic breast cancer will develop drug resistance and progress. The mechanisms of resistance to endocrine therapy can be divided into two categories. One category focuses on the estrogen receptor signaling pathway itself, including activating mutations, amplification, and fusion with other genes of the gene ESR1 encoding the estrogen receptor, and the dysregulation of estrogen receptor co-regulators and downstream cell cycle control factors. The other mechanism includes the activation of signaling pathways that cross-react with the estrogen receptor signaling pathway, such as the growth factor receptor pathway (Nat Rev Clin Oncol. 2015 Oct; 12(10): 573-83).
[0004] In 2013, two studies detected ESR1 gene mutations in 11-55% of estrogen receptor-positive metastatic breast cancer patients who had been treated with aromatase inhibitors. Further studies found that the mutated receptor can be phosphorylated independently of estrogen and exert transcriptional effects, making the estrogen-dependent MCF7-inoculated tumors no longer dependent on estrogen for growth in vivo. In addition, the mutated receptor reduces the activity of SERM tamoxifen and SERD fulvestrant. Therefore, ESR1 gene mutation may be one of the mechanisms of drug resistance in estrogen-positive breast cancer (Nat Rev Clin Oncol. 2015 Oct; 12 (10): 573-83 and Nat Genet 2013; 45: 1439–45). In subsequent studies, a certain proportion of ESR1 gene mutations were found in estrogen receptor-positive metastatic breast cancer patients, with the mutation ratio being about 30%. In the BOLERO-2 clinical trial, 29% of ctDNA of patients with estrogen receptor-positive metastatic breast cancer who progressed after AIs treatment contained ER Y537S and ER D538G mutations. In the exemestane monotherapy group, patients with mutations had shorter progression-free survival (PFS) and overall survival (OS) than those without mutations [Nat Genet 2013; 45: 1446–51].
[0005] In summary, ESR1 gene mutations mostly occur in patients with metastatic estrogen receptor-positive breast cancer that progress after AIs treatment. These patients are no longer sensitive to AIs treatment, so it is necessary to develop estrogen receptor antagonists targeting ESR1 gene mutations.
[0006] The first-in-class estrogen receptor covalent binding antagonist H3B-6545 developed by Eisai has strong inhibitory activity against both wild-type and mutant estrogen receptors, and can exert a longer-lasting drug effect through covalent binding to the receptor. It is currently undergoing phase I and II clinical trials. The currently disclosed patents for estrogen receptor antagonists targeting ESR1 gene mutations are WO2016196346 and WO2016196342.
[0007] WO2020253762 discloses an indazole derivative, whose chemical name is (E)-1-morpholinyl-4-((1-(((5-((Z)-4,4,4-trifluoro-1-(3-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)pyridin-2-yl)oxy)methyl)cyclopropyl)amino)but-2-en-1-one (Formula I), providing patients with a new treatment option. Summary of the invention
[0008] The present disclosure provides a maleate IV crystalline form of a compound represented by formula (I), wherein the molar ratio of the compound represented by formula (I) to maleic acid is 1:2-2:1, preferably 1:1, and its X-ray powder diffraction spectrum has characteristic peaks at 2θ angles of 8.644, 15.597, 16.444, 17.091, 20.983, 23.463 and 24.038,
[0009]
[0010] In some embodiments, the IV crystal form of the maleate salt of the compound represented by formula (I) has an X-ray powder diffraction spectrum with characteristic peaks at 2θ angles of 8.644, 15.597, 16.444, 17.091, 19.439, 20.048, 20.983, 23.463, 24.038 and 27.871.
[0011] In some embodiments, the IV crystal form of the maleate salt of the compound represented by formula (I) has an X-ray powder diffraction spectrum with characteristic peaks at 2θ angles of 8.644, 9.243, 13.937, 14.874, 15.597, 16.444, 17.091, 19.439, 20.048, 20.983, 23.463, 24.038 and 27.871.
[0012] In some embodiments, the IV crystalline form of the maleate salt of the compound represented by formula (I) has an X-ray powder diffraction spectrum with characteristic peaks at 2θ angles of 8.644, 9.243, 13.937, 14.874, 15.597, 16.444, 17.091, 17.836, 18.916, 19.439, 20.048, 20.983, 22.161, 22.755, 23.463, 24.038, 25.002, 25.724, 26.322, 27.871, 28.293, 28.743, 29.840, 30.764, 31.629, 32.367, 33.012, and 35.433.
[0013] In some embodiments, the X-ray powder diffraction spectrum of the IV crystalline form of the maleate salt of the compound represented by formula (I) is as follows: Figure 1 shown.
[0014] Another aspect of the present disclosure provides a method for preparing a maleate salt of a compound represented by formula (I) in crystal form IV, the method comprising the following steps:
[0015] 1) dissolving the compound represented by formula (I) and maleic acid in at least one solvent selected from ethanol, acetonitrile, butanone, n-hexane, isopropanol and ethyl acetate,
[0016] 2) Crystallization.
[0017] Furthermore, in the IV crystalline form of the maleate salt of the compound of formula (I) prepared above, the molar ratio of the compound of formula (I) to maleic acid is 1:2-2:1, preferably 1:1.
[0018] In certain embodiments, the method for preparing the crystalline form described in the present disclosure further comprises filtering, washing or drying steps.
[0019] The present disclosure also provides a pharmaceutical composition prepared from a pharmaceutically acceptable salt of the compound represented by the aforementioned formula (I) or a crystalline form of a pharmaceutically acceptable salt.
[0020] The present disclosure also provides a pharmaceutical composition comprising the following components: i) the IV crystal form of the compound represented by the aforementioned formula (I) or the IV crystal form of the compound represented by the aforementioned formula (I) prepared by the aforementioned method, and ii) any pharmaceutically acceptable carrier, diluent or excipient.
[0021] The present disclosure also provides a method for preparing a pharmaceutical composition, comprising the step of mixing the aforementioned component i) and component ii).
[0022] The present disclosure also provides the IV crystal form of the compound represented by the aforementioned formula (I), or the IV crystal form of the compound represented by the aforementioned method prepared by the aforementioned method, or the aforementioned composition, or the use of the composition prepared by the aforementioned method in the preparation of a drug for preventing and / or treating estrogen receptor-mediated or dependent diseases or conditions.
[0023] In some embodiments, the estrogen receptor mediated or dependent disease or condition is cancer.
[0024] In some embodiments, the estrogen receptor-mediated or -dependent disease or condition is selected from breast cancer, ovarian cancer, endometrial cancer, prostate cancer, or uterine cancer.
[0025] In some embodiments, the estrogen receptor mediated or dependent disease or condition is breast cancer.
[0026] The "2θ or 2θ angle" described in the present disclosure refers to the diffraction angle, θ is the Bragg angle, and the unit is ° or degree; the error range of each characteristic peak 2θ is ±0.20, which can be -0.20, -0.19, -0.18, -0.17, -0.16, -0.15, -0.14, -0.13, -0.12, -0.11, -0.10, -0.09, -0.08, -0.07, -0.06, -0.05, -0.04, -0.03, -0.02, -0.01, 0.00, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20.
[0027] The "crystallization" described in the present disclosure includes but is not limited to stirring crystallization, slurry crystallization and volatilization crystallization.
[0028] The drying temperature in the present disclosure is generally 25° C.-100° C., preferably 40° C.-70° C., and the drying can be performed under normal pressure or reduced pressure. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 XRPD spectrum of Form IV of the maleate salt of the compound represented by formula (I);
[0030] Figure 2 . DSC spectrum of Form IV of the maleate salt of the compound represented by formula (I);
[0031] Figure 3 . TGA spectrum of Form IV of the maleate salt of the compound represented by formula (I);
[0032] Figure 4 . DVS spectrum of Form IV of the maleate salt of the compound represented by formula (I); DETAILED DESCRIPTION
[0033] The present invention will be explained in more detail below in conjunction with embodiments. The embodiments of the present invention are only used to illustrate the technical solutions of the present invention, and are not intended to limit the essence and scope of the present invention.
[0034] Test conditions of the instruments used in the experiment:
[0035] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10 -6The unit of (ppm) is given. NMR measurements were performed using a Bruker AVANCE-400 nuclear magnetic spectrometer or a Bruker AVANCE NEO 500M, with deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD) as the measurement solvent, and tetramethylsilane (TMS) as the internal standard.
[0036] MS was measured using Agilent 1200 / 1290 DAD-6110 / 6120 Quadrupole MS liquid spectrometer-mass spectrometer (manufacturer: Agilent, MS model: 6110 / 6120 Quadrupole MS).
[0037] waters ACQuity UPLC-QD / SQD (Manufacturer: waters, MS model: waters ACQuity QdaDetector / waters SQ Detector)
[0038] THERMO Ultimate 3000-Q Exactive (Manufacturer: THERMO, MS model: THERMOQExactive)
[0039] High performance liquid chromatography (HPLC) analysis was performed using Agilent HPLC 1200DAD, Agilent HPLC 1200VWD and Waters HPLC e2695-2489.
[0040] Chiral HPLC analysis was performed using an Agilent 1260DAD high performance liquid chromatograph.
[0041] High performance liquid chromatography was performed using Waters 2545-2767, Waters 2767-SQ Detecor2, Shimadzu LC-20AP and Gilson GX-281 preparative chromatographs.
[0042] Chiral preparations were performed using a Shimadzu LC-20AP preparative chromatograph.
[0043] Ion chromatography was performed using Thermo Scientific Dionex Intergrion column model: Dionex IonPacTM AS11-HC (4 μm, 4×250 cm).
[0044] XRPD is X-ray powder diffraction detection: the measurement is carried out using a BRUKER D8 Discover X-ray diffractometer, and the specific collection information is: Cu anode (40kV, 40mA), Cu-Kα ray Scanning mode: θ / 2θ, scanning range (2θ range): 3~50°.
[0045] DSC is differential scanning calorimetry: the measurement was performed using a METTLER TOLEDO DSC 3+ differential scanning calorimeter, with a heating rate of 10°C / min, the specific temperature range refers to the corresponding spectrum (mostly 25-300 or 25-350°C), and a nitrogen purge rate of 50 mL / min.
[0046] TGA is thermogravimetric analysis: the test was performed using a METTLER TOLEDO TGA 2 thermogravimetric analyzer, with a heating rate of 10°C / min, the specific temperature range referred to the corresponding spectrum (mostly 25-300°C), and a nitrogen purge rate of 50 mL / min.
[0047] DVS stands for dynamic moisture adsorption: SMSDVS Advantage is used for detection. At 25°C, the humidity changes from 50% to 95% to 0% to 95% to 50%, with a step of 10% (the last step is 5%) (the specific range of humidity is subject to the corresponding graph, and most of the methods listed here are used). The judgment standard is that dm / dt is not greater than 0.002%.
[0048] Unless otherwise specified in the examples, the solution refers to an aqueous solution.
[0049] Unless otherwise specified in the examples, the reaction temperature is room temperature, 20°C to 30°C.
[0050] The reaction progress in the embodiment is monitored by thin layer chromatography (TLC), the developing solvent used in the reaction, the eluent system of column chromatography used for purifying the compound and the developing solvent system of thin layer chromatography include: A: dichloromethane / methanol system, B: n-hexane / ethyl acetate system, the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.
[0051] Example 1. Preparation of maleate IV crystalline form
[0052] The compound of formula I (1.5 g, 2.36 mmol) was added to 50 mL of acetonitrile, stirred, heated to 60°C, dissolved, and 5 mL of acetonitrile solution of maleic acid (301.3 mg, 2.6 mmol) was slowly added dropwise, stirred at 60°C, dissolved for 2 hours, stirred at room temperature for 16 hours to form a white turbid liquid, filtered, the filter cake was collected, and vacuum dried to obtain the title product (1.4 g, yield: 93.3%).
[0053] Ion chromatography showed that the maleic acid ion content was 14.85%, indicating that the molar ratio of the main component to maleic acid in the salt was 1:1.
[0054] The product 1 H-NMR characterization and nuclear magnetic resonance data showed that the molar ratio of the main component to maleic acid in the salt was 1:1.
[0055] 1 H NMR (400MHz, CD3OD) δ7.73-7.64(m,2H),7.52(dd,1H),7.32(dd,3H),7.26(d,4H),6.82(d,1H),6.75-6.63(m,2H),6.2 6(s,2H),4.41(s,2H),4.01(d,2H),3.63-3.56(m,8H),3.46(d,1H),3.44-3.35(m,1H),1.17(d,2H),1.16-1.05(m,2H).
[0056] The product was defined as Form IV by X-ray powder diffraction. Figure 1 , the peak positions are shown in Table 1.
[0057] DSC spectrum Figure 2 The endothermic peak value is 165.08℃; TGA spectrum Figure 3 It shows a weight loss of 3.1709% at 25℃-155℃. DVS test shows that under normal storage conditions (i.e. 25℃, 60%RH), the sample has a moisture absorption weight gain of about 0.15%; under accelerated experimental conditions (i.e. 70%RH), the moisture absorption weight gain is about 0.17%; under extreme conditions (90%RH), the moisture absorption weight gain is about 0.24%. During the humidity change process from 0% to 95%RH, the desorption process of the sample basically coincides with the adsorption process. After DVS test, the crystal form was retested and the crystal form did not change.
[0058] Table 1. Maleate IV crystal peak position
[0059]
[0060]
[0061] Example 2, Preparation of Maleate IV Crystalline Form
[0062] Add 0.5 mL of maleic acid (4.6 mg, 39.3 μmol) in butanone solution to the compound of formula I (25 mg, 39.33 μmol), stir until dissolved, then add 0.5 mL of n-hexane and stir. After 0.5 hour, a white turbid liquid gradually forms. Stir at room temperature for 16 hours, filter, collect the filter cake, and vacuum dry to obtain the title product (20 mg, yield: 80%). X-ray powder diffraction detection shows that the product is crystal form IV.
[0063] Example 3. Preparation of maleate IV crystalline form
[0064] The compound shown in formula I (50 mg, 78.66 μmol) was added to 2 mL of isopropanol and stirred, heated to 60°C, dissolved, and then slowly added dropwise 0.5 mL of isopropanol solution of maleic acid (10.04 mg, 86.52 μmol), stirred at 60°C to dissolve, stirred at room temperature for 16 hours to form a white turbid liquid, filtered, collected the filter cake, and vacuum dried to obtain the title product (40 mg, yield: 80%). The product was crystal form IV as determined by X-ray powder diffraction.
[0065] Example 4. Preparation of maleate IV crystalline form
[0066] The compound shown in formula I (550 mg, 865.26 μmol) was added to 15 mL of ethanol and stirred, heated to 40°C, completely dissolved, and maleic acid (110.48 mg, 951.78 μmol) ethanol solution was added dropwise, stirred to dissolve, and 15 mL of n-hexane was added and stirred. After 0.5 hours, the mixture was cooled to room temperature and stirred for 16 hours to form a white turbid liquid. The mixture was filtered, the filter cake was collected, and vacuum dried to obtain the title product (500 mg, yield: 90.9%). The product was crystal form IV as detected by X-ray powder diffraction.
[0067] Example 5: Experiment on factors affecting maleate IV crystal form
[0068] The maleate IV crystalline form of the compound of formula I was placed in an open clean weighing bottle, and the stability of the sample was investigated under high temperature (40°C, 60°C), light (4500lx±500lx), and high humidity (90%±5%, 75%±5%) conditions. The sampling period was 30 days, and the results are shown in Table 2 below.
[0069] Table 2. 30-day test results of factors affecting the crystal form of maleate IV of Formula I
[0070]
[0071]
[0072] The experimental results show that the maleate IV crystalline form of the compound of formula I has good stability in physical and chemical properties under the conditions of light, 40° C., 60° C., 75% RH, and 90% RH.
[0073] Example 6: Long-term accelerated stability test of maleate IV crystal
[0074] The maleate IV crystalline form of the compound of formula I was subjected to long-term (25°C, 60% RH) and accelerated (40°C, 75% RH) stability tests for 6 months. The results are shown in Table 3 below.
[0075] Table 3
[0076]
[0077] The results showed that the maleate IV crystal sample had good physicochemical stability when placed under long-term (25°C, 60% RH) and accelerated (40°C, 75% RH) conditions for 6 months.
[0078] Example 7: Study on Hygroscopicity of Maleate IV Crystal Form of Compound I
[0079] Using Surface Measurement Systems advantage 2, at 25°C, humidity started from 50%, and the humidity range was 0%-95% with a step of 10%. The judgment criteria were that the mass change dM / dT of each gradient was less than 0.002 and TMAX was less than 360min. Two cycles were repeated. The experimental results are shown in Table 4.
[0080] Table 4
[0081]
[0082] Example 8. Solubility test of maleate IV crystal of compound of formula I in FassiF solution, PBS 7.4 solution, FessiF solution and water
[0083] Test Example 1: Solubility test of maleate IV crystal form of compound of formula I in FassiF solution
[0084] 1. Experimental steps
[0085] 1.1 Preparation of FassIF solution
[0086] Solution (A): Add 4.441 g NaH2PO4·2H2O, 0.348 g NaOH pellets and 6.186 g NaCl to 900 mL ultrapure water, mix well, and add 1 M NaOH to adjust the pH of the solution to 6.5 ± 0.05, and dilute to 1000 mL with water. Refrigerate at 4°C until use.
[0087] FassIF solution (B): Dissolve 0.161 g of sodium taurocholate (NaTC, molecular weight 537.68) and 59 mg of lecithin (molecular weight 788.13) in 20 mL of solution (A), stir vigorously overnight to form a clear micellar solution, add solution (A) to the volume of 100 mL, and refrigerate at 4°C for use (no more than 2 weeks).
[0088] 1.2 Weigh an appropriate amount of the compound to be tested and use DMSO as solvent to prepare a 10mM stock solution. Accurately measure 10μL of the stock solution (concentration 10mM, dissolved in DMSO) and 990μL of an organic mixed solvent (usually DMSO: acetonitrile: ethanol = 1:1:1) in a 2mL sample bottle and mix well to obtain a clear 100μM sample solution as a reference solution.
[0089] 1.3 Dissolve 1 mg of the sample to be tested in 900 μL FassIF solution (B), mix vigorously, and prepare two solutions in parallel; shake in a 37°C water bath for 24 hours, centrifuge at 4000 rpm for 30 minutes, and transfer the supernatant as the sample solution to liquid chromatography analysis.
[0090] 2. Data processing
[0091] FassIF solubility (μM) = peak area of sample / peak area of reference*concentration of reference solution (μM)*dilution factor of sample solution. The average of two measurements was taken. The test results are shown in Table 4 below.
[0092] Test Example 2: Solubility test of maleate IV crystal of Formula I compound in PBS 7.4 solution
[0093] 1. Experimental steps
[0094] 1.1 Preparation of pH 7.4 PBS solution: weigh 0.57g NaH2PO4·2H2O, 5.55g Na2HPO4·12H2O and 6.48g NaCl, add ultrapure water, adjust pH to 7.4±0.05 with 1M NaOH or 1M HCl, and add water to make up to 1L. Store in a refrigerator at 4℃ (shelf life is 6 months)
[0095] 1.2 Preparation of compound PBS 7.4 solution: Weigh an appropriate amount of the test compound and dissolve it with DMSO or DMSO: acetonitrile: ethanol = 1:1:1 to prepare a 10mM test compound stock solution. Accurately measure 10μL of the test compound stock solution and 990μL pH7.4 PBS solution in a 2mL sample bottle and mix well. The final solution DMSO concentration is 1% (v / v). The solution is prepared in parallel in duplicate, shaken at room temperature for 24 hours on a flat bed, centrifuged at 5000rpm for 20min, and the supernatant is transferred to a liquid chromatograph for analysis.
[0096] 1.3 Preparation of reference solution: Accurately measure 10 μL of the sample stock solution (concentration 10 mM, dissolved in DMSO) and 990 μL of organic mixed solvent (usually DMSO: acetonitrile: ethanol = 1:1:1) in a 2 mL sample bottle, mix well, and obtain a clear 100 μM sample solution. Filter with a 0.45 μm organic phase microporous filter membrane, and the filtrate is analyzed by liquid chromatography.
[0097] 2. Data processing
[0098] Solubility (μM) = peak area of sample / peak area of reference*reference concentration (μM)*dilution factor of sample solution. The average of two measurements was taken. The test results are shown in Table 4 below.
[0099] Test Example 3: Solubility test of maleate IV crystal form of compound of formula I in FessiF solution
[0100] 1. Experimental steps
[0101] 1.1 Preparation of FessIF solution
[0102] Solution (A): Accurately weigh 20.2 g NaOH pellets, 43.25 g glacial acetic acid and 59.37 g sodium chloride, dissolve in appropriate amount of ultrapure water and make up to 5 L, adjust pH to 5.0 with 1 M NaOH or 1 M HCl. Refrigerate at 4°C until use.
[0103] FessIF solution (B): Dissolve 0.80652 g of sodium taurocholate (NaTC, molecular weight 537.68) and 295.5 mg of lecithin (molecular weight 788.13) in 25 mL of solution (A), stir vigorously overnight to form a clear micellar solution, add solution (A) to the volume of 100 mL, and refrigerate at 4°C for use (no more than 2 weeks).
[0104] 1.2 Weigh an appropriate amount of the compound to be tested and use DMSO as solvent to prepare a 10mM stock solution. Accurately measure 10μL of the stock solution (concentration 10mM, dissolved in DMSO) and 990μL of an organic mixed solvent (usually DMSO: acetonitrile: ethanol = 1:1:1) in a 2mL sample bottle and mix well to obtain a clear 100μM sample solution as a reference solution.
[0105] 1.3 Dissolve 1 mg of the sample to be tested in 900 μL FessIF solution (B), mix vigorously, and prepare two solutions in parallel; shake in a 37°C water bath for 24 hours, centrifuge at 4000 rpm for 30 minutes, and transfer the supernatant as the sample solution to liquid chromatography analysis.
[0106] 2. Data processing
[0107] FessIF solubility (μM) = peak area of sample / peak area of reference*concentration of reference solution (μM)*dilution factor of sample solution. The average of two measurements is taken. The test results are shown in Table 4 below.
[0108] Test Example 4: Solubility test of maleate IV crystal form of compound of formula I in water
[0109] Weigh a certain amount of fixed sample, add an appropriate volume of aqueous solution to prepare a saturated solution, stir magnetically for 24 hours, test the pH value of the solution, centrifuge the solution at 4000 rpm for 30 minutes, and transfer the supernatant as the sample solution to liquid chromatography analysis using the same method as above. The test results are shown in Table 5 below.
[0110] Table 5
[0111]
Claims
1. A crystalline form IV of a maleate salt of a compound represented by formula (I), wherein the molar ratio of the compound represented by formula (I) to maleic acid is 1:2-2:1, preferably 1:1, and its X-ray powder diffraction spectrum has characteristic peaks at 2θ angles of 8.644, 15.597, 16.444, 17.091, 20.983, 23.463 and 24.038, 2. The IV crystalline form of the maleate salt of the compound represented by formula (I) according to claim 1 has characteristic peaks in its X-ray powder diffraction spectrum at 2θ angles of 8.644, 15.597, 16.444, 17.091, 19.439, 20.048, 20.983, 23.463, 24.038 and 27.
871.
3. According to claim 1, the IV crystalline form of the maleate salt of the compound represented by formula (I) has characteristic peaks at 2θ angles of 8.644, 9.243, 13.937, 14.874, 15.597, 16.444, 17.091, 19.439, 20.048, 20.983, 23.463, 24.038 and 27.871; preferably, the IV crystalline form of the maleate salt of the compound represented by formula (I) has an X-ray powder diffraction spectrum as shown in Figure 1.
4. The IV crystalline form of the maleate salt of the compound of formula (I) according to any one of claims 1 to 3, wherein: The error range of the 2θ angle is ±0.
2.
5. A method for preparing the IV crystalline form of the maleate salt of the compound of formula (I) according to any one of claims 1 to 4, the method comprising the following steps: 1) dissolving the compound represented by formula (I) and maleic acid in at least one solvent selected from ethanol, acetonitrile, butanone, n-hexane, isopropanol and ethyl acetate, 2) Crystallization.
6. A composition prepared from the IV crystalline form of the maleate salt of the compound of formula (I) according to any one of claims 1 to 4 and the IV crystalline form of the maleate salt prepared according to the method of claim 5.
7. A pharmaceutical composition comprising the following components: i) Form IV of the maleate of the compound of formula (I) according to any one of claims 1 to 4, or Form IV of the maleate prepared by the method according to claim 5; and ii) one or more pharmaceutically acceptable carriers, diluents or excipients.
8. A method for preparing a pharmaceutical composition, comprising the step of mixing the IV crystalline form of the maleate salt of the compound of formula (I) according to any one of claims 1 to 4, the IV crystalline form of the maleate salt prepared by the method according to claim 5, and a pharmaceutically acceptable carrier, diluent or excipient.
9. Use of the IV crystalline form of the maleate salt of the compound of formula (I) according to any one of claims 1 to 4, the IV crystalline form of the maleate salt prepared by the method according to claim 5, the composition according to claim 7 or the composition prepared by the method according to claim 8 in the preparation of a medicament for preventing and / or treating estrogen receptor-mediated or dependent diseases or conditions.
10. The use according to claim 9, wherein the estrogen receptor-mediated or -dependent disease or condition is cancer, preferably breast cancer, ovarian cancer, endometrial cancer, prostate cancer or uterine cancer, more preferably breast cancer.
